<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512794</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-22</org_study_id>
    <nct_id>NCT04512794</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation</brief_title>
  <acronym>PLASZMA</acronym>
  <official_title>Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation An AcQMap Substrate Characterization Study (PLASZMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acutus Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acutus Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation: An AcQMap Substrate&#xD;
      Characterization Study (PLASZMA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AcQMap Imaging and Mapping System® is intended for use in patients for whom&#xD;
      electrophysiology procedures have been prescribed.&#xD;
&#xD;
      When used with the AcQMap Catheters, the AcQMap System is intended to be used to reconstruct&#xD;
      the selected chamber from ultrasound data for purposes of visualizing the chamber anatomy and&#xD;
      displaying electrical impulses as either charge density-based or voltage-based maps of&#xD;
      complex arrhythmias that may be difficult to identify using conventional mapping systems&#xD;
      alone.&#xD;
&#xD;
      AND&#xD;
&#xD;
      When used with specified Patient Electrodes, the AcQMap System is intended to display the&#xD;
      position of the AcQMap Catheters and conventional electrophysiology (EP) catheters in the&#xD;
      heart.&#xD;
&#xD;
      OR&#xD;
&#xD;
      When used with conventional electrophysiology catheters, the AcQMap System provides&#xD;
      information about the electrical activity of the heart and about catheter location during the&#xD;
      procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The subject population will consist of men and women 18 years of age or older presenting for a de novo ablation of a symptomatic, complex atrial arrhythmia including atrial fibrillation/atrial tachycardia/atrial flutter</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Device/Procedure Related Major Adverse Events (MAEs)</measure>
    <time_frame>6 Months</time_frame>
    <description>MAEs inlcude: death, myocardial infarction, cardiac perforation/tamponade, cerebral infarct, or systemic embolism, Major bleeding requiring transfusion of blood products, Mitral or tricuspid valve damage, Symptomatic pulmonary vein (PV) stenosis, Asymptomatic PV stenosis ≥ 70%, Permanent phrenic nerve injury, Access site complications requiring pharmacological or surgical intervention, Atrio-esophageal fistula, Pericarditis, Heart block requiring a permanent pacemaker, Vagal nerve injury leading to gastroparesis, Other serious adverse device effects (SADEs), including transient ischemic attack (TIAs), adjudicated as &quot;probably or definitely related&quot; to the AcQMap System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced at Least One procedure and device related Serious Adverse Events.serious adverse device effects (SADEs), and all unanticipated device effects (UADEs)</measure>
    <time_frame>6 Months</time_frame>
    <description>Recording of all SAEs/SADEs/UADEs through 6-months-procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects who are free from AF/AT/AFL (following a 90-day blanking period)</measure>
    <time_frame>12 Months</time_frame>
    <description>Time to first event of any atrial arrhythmia from day 91 through 12 months.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Non-randomized</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects with de novo ablation procedure for an atrial arrhythmia using the AcQMap System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcQMap High Resolution Imaging and Mapping System</intervention_name>
    <description>Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.</description>
    <arm_group_label>Non-randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age at the time of consent&#xD;
&#xD;
          2. Clinically indicated and scheduled for a de novo catheter ablation of a complex left&#xD;
             atrial arrhythmia including AF/AT/AFL&#xD;
&#xD;
          3. Willing and able to provide written informed consent to participate in the study and&#xD;
             agree to comply with all follow-up visits and evaluations for the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, any contraindication to the planned atrial&#xD;
             ablation, including anticoagulation contraindications, renal failure, or sepsis.&#xD;
&#xD;
          2. Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other&#xD;
             reversible or non-cardiac cause.&#xD;
&#xD;
          3. Any DCCV within 60-days of the index procedure where sinus rhythm was not maintained&#xD;
             for at least 60-minutes.&#xD;
&#xD;
          4. Any cardiac defibrillator (ICD) or pacemaker implanted within 8-weeks prior to the&#xD;
             ablation procedure.&#xD;
&#xD;
          5. History of previous left atrial ablation (including surgical treatment) for AF/AT/AFL.&#xD;
&#xD;
          6. Structural heart disease or cardiac history including:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 35% based on a 2-d transthoracic&#xD;
                  echocardiogram (TTE) within the previous 180-days prior to enrollment.&#xD;
&#xD;
               2. Left atrial size &gt; 60 mm (parasternal long-axis view) based on 2-d TTE within the&#xD;
                  previous 180-days prior to enrollment.&#xD;
&#xD;
               3. Prior history of New York Heart Association (NYHA) Class IV heart failure.&#xD;
&#xD;
               4. Any evidence of NYHA Class III heart failure in the previous 3-months prior to&#xD;
                  enrollment.&#xD;
&#xD;
               5. Unstable angina or ongoing myocardial ischemia.&#xD;
&#xD;
               6. Myocardial infarction (STEMI) within the previous 180-days (sub-endocardial&#xD;
                  infarct within previous 90-days) prior to enrollment.&#xD;
&#xD;
               7. Moderate or severe valvular heart disease (stenosis or regurgitation).&#xD;
&#xD;
               8. Presence of a left atrial appendage occlusion device.&#xD;
&#xD;
          7. Body Mass Index (BMI) &gt; 40kg/m2&#xD;
&#xD;
          8. History of blood clotting or bleeding disease.&#xD;
&#xD;
          9. History of chronic obstructive pulmonary disease (COPD) requiring use of oxygen in the&#xD;
             treatment regimen.&#xD;
&#xD;
         10. History of obstructive sleep apnea not currently being treated.&#xD;
&#xD;
         11. Pregnant or lactating (current or anticipated during study follow-up).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerald L Cox</last_name>
    <phone>760-529-6310</phone>
    <email>jerry.cox@acutus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deana Pierce</last_name>
    <phone>7606379109</phone>
    <email>deana.pierce@acutus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner University Medical Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Weiss, MD</last_name>
      <email>peteweissmd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jimmy Schohn</last_name>
      <email>James.schohn@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Leon Feldman, MD</last_name>
      <email>lfeldman@desertcard.com</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Kunic, RN</last_name>
      <email>SKunic@eisenhowerhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Leon Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Celebration Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Lexington Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerry Tomassoni, MD</last_name>
      <email>gery.tomassoni@bhsi.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristie Schneider, RN</last_name>
      <email>KSchneid@BHSI.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerry Tomassoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ablation</keyword>
  <keyword>atrial arrhythmias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

